{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:04:45Z","timestamp":1789830285817,"version":"4.0.1"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordination for the improvement of Higher Education Personnel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Carlos Chagas Filho Foundation for Research Support of Rio de Janeiro State","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clnu.2026.106781","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:52:23Z","timestamp":1788364343000},"page":"106781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Modern pharmacological therapies in nephrology: Progress, promises, and the forgotten role of diet"],"prefix":"10.1016","volume":"65","author":[{"given":"Nat\u00e1lia Alvarenga","family":"Borges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila Ferreira Medeiros de Fran\u00e7a","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane de","family":"Oliveira Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia de S\u00e1 Fernandes Vallim","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Wesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Fouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-6056","authenticated-orcid":false,"given":"Denise","family":"Mafra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2026.106781_bib1","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants","volume":"404","author":"Zhou","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clnu.2026.106781_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clnu.2026.106781_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0325182","article-title":"Approaches to predict future type 2 diabetes mellitus and chronic kidney disease: a scoping review","volume":"20","author":"Bu\u00dfmann","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.clnu.2026.106781_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14238326","article-title":"Diabetes mellitus and chronic kidney disease: the future is being surpassed","volume":"14","author":"Mart\u00ednez-Castelao","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.clnu.2026.106781_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0140-6736(25)01942-7","article-title":"Chronic kidney disease","volume":"407","author":"Herrington","year":"2026","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clnu.2026.106781_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41581-020-00345-8","article-title":"Food as medicine: targeting the uraemic phenotype in chronic kidney disease","volume":"17","author":"Mafra","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.clnu.2026.106781_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70184","article-title":"Beyond glycemic control: how incretins are changing the cardiovascular trajectories of diabetes and obesity","volume":"56","author":"Avogaro","year":"2026","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clnu.2026.106781_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/dom.70506","article-title":"Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: systematic review and meta-analysis","volume":"28","author":"Abdel-Rahman","year":"2026","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnu.2026.106781_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-024-01805-z","article-title":"Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis","volume":"24","author":"Teng","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.clnu.2026.106781_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/healthcare12232464","article-title":"Hemodynamic effects of SGLT2 inhibitors in patients with and without diabetes Mellitus-A narrative review","volume":"12","author":"Brata","year":"2024","journal-title":"Healthcare"},{"key":"10.1016\/j.clnu.2026.106781_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.clnu.2026.106781_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118731","article-title":"Comparative safety and side effects of semaglutide and tirzepatide: implications for clinical decision-making in obesity management","volume":"193","author":"Fahim","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clnu.2026.106781_bib13","article-title":"Pharmacology and therapeutic potential of finerenone: a novel third-generation nonsteroidal mineralocorticoid receptor antagonist","volume":"17","author":"Ramadan","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.clnu.2026.106781_bib14","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/ndt\/gfae216","article-title":"Upcoming drug targets for kidney protective effects in chronic kidney disease","volume":"40","author":"Nardone","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clnu.2026.106781_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnu.2026.106781_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41581-024-00908-z","article-title":"Endothelin receptor antagonists in chronic kidney disease","volume":"21","author":"Smeijer","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.clnu.2026.106781_bib17","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-025-00995-3","article-title":"Gastrointestinal motility effects of GLP-1 receptor agonists","volume":"27","author":"Bellavance","year":"2025","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.clnu.2026.106781_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clnu.2026.106781_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/dia.2014.0188","article-title":"Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"17","author":"Sun","year":"2015","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.clnu.2026.106781_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clnu.2026.106781_bib21","article-title":"Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA adverse event reporting system database","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clnu.2026.106781_bib22","article-title":"Acute pancreatitis caused by tirzepatide","volume":"16","author":"Mando","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.clnu.2026.106781_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.clnu.2026.106781_bib24","article-title":"Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials","volume":"18","author":"Bundhun","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.clnu.2026.106781_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgaa586","article-title":"Clinical adverse events of high-dose vs low-dose sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of 51 randomized clinical trials","volume":"105","author":"Shi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clnu.2026.106781_bib26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s13300-018-0399-z","article-title":"Adverse drug events associated with low-dose (10 mg) versus high-dose (25 mg) empagliflozin in patients treated for type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Dai","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clnu.2026.106781_bib27","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.amjcard.2019.10.029","article-title":"Safety of sodium-glucose Co-Transporter 2 inhibitors","volume":"124","author":"McGill","year":"2019","journal-title":"American Journal of Cardiology"},{"key":"10.1016\/j.clnu.2026.106781_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.clnu.2026.106781_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.clnu.2026.106781_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26168096","article-title":"Targeting sarcopenia in CKD: the emerging role of GLP-1 receptor agonists","volume":"26","author":"Llinares-Arvelo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnu.2026.106781_bib31","article-title":"Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes: a systematic review incorporating an indirect comparisons meta-analysis","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clnu.2026.106781_bib32","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/ndt\/gfae241","article-title":"Mineralocorticoid receptor antagonism for non-diabetic kidney disease","volume":"40","author":"Jaisser","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clnu.2026.106781_bib33","doi-asserted-by":"crossref","DOI":"10.2174\/0118715303350851241021105850","article-title":"Improving renal protection in chronic kidney disease associated with type 2 diabetes: the role of finerenone","volume":"25","author":"Nugroho","year":"2025","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.clnu.2026.106781_bib34","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/ndt\/gfac284","article-title":"Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?","volume":"38","author":"Gregg","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clnu.2026.106781_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13206056","article-title":"Endothelin inhibitors in chronic kidney disease: new treatment prospects","volume":"13","author":"Rakotoarison","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.clnu.2026.106781_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043427","article-title":"Endothelin receptor antagonists in kidney disease","volume":"24","author":"Mart\u00ednez-D\u00edaz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnu.2026.106781_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2025.2465810","article-title":"The role of endothelin receptor antagonists in kidney disease","volume":"47","author":"Ma","year":"2025","journal-title":"Ren Fail"},{"key":"10.1016\/j.clnu.2026.106781_bib38","article-title":"The relationship between obesity and chronic kidney disease: conclusions from a Kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"109","author":"Furth","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.clnu.2026.106781_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnu.2026.106781_bib40","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/eurheartj\/ehae613","article-title":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial","volume":"46","author":"Mahaffey","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clnu.2026.106781_bib41","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jacc.2025.03.009","article-title":"Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial","volume":"85","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clnu.2026.106781_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaf193","article-title":"The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis","volume":"41","author":"Sasaki","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clnu.2026.106781_bib43","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1111\/dom.15967","article-title":"Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: a prospective, observational, open-label study","volume":"26","author":"Vanek","year":"2024","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnu.2026.106781_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaf199","article-title":"GLP-1 receptor agonists for kidney transplant recipients","volume":"41","author":"Schmitz","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clnu.2026.106781_bib45","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clnu.2026.106781_bib46","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.clnu.2026.106781_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.20835","article-title":"Effects of sodium glucose cotransporter 2 inhibitors by diabetes status and level of albuminuria: a meta-analysis","volume":"335","author":"Staplin","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.clnu.2026.106781_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2025.20834","article-title":"SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis","volume":"335","author":"Neuen","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.clnu.2026.106781_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-86172-y","article-title":"Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease","volume":"15","author":"Hunsuwan","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2026.106781_bib50","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1007\/s00125-024-06251-z","article-title":"Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care","volume":"67","author":"Fadini","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.clnu.2026.106781_bib51","article-title":"Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes","volume":"5","author":"Natale","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clnu.2026.106781_bib52","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clnu.2026.106781_bib53","article-title":"Finerenone's impact on major adverse cardiovascular events in chronic kidney disease and type 2 diabetes mellitus: a systematic review","volume":"16","author":"Murugan","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.clnu.2026.106781_bib54","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa2512854","article-title":"Finerenone in type 1 diabetes and chronic kidney disease","volume":"394","author":"Heerspink","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnu.2026.106781_bib55","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.0000000928","article-title":"Meta-Analysis of randomized controlled trials assessing the efficacy and safety of Endothelin receptor antagonists in CKD","volume":"21","author":"Shi","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clnu.2026.106781_bib56","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.0000000000000436","article-title":"Effects of Zibotentan alone and in combination with dapagliflozin on fluid retention in patients with CKD","volume":"35","author":"Smeijer","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clnu.2026.106781_bib57","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/HYPERTENSIONAHA.119.12919","article-title":"Endothelin receptor antagonism improves lipid profiles and lowers PCSK9 (Proprotein convertase Subtilisin\/Kexin type 9) in patients with chronic kidney disease","volume":"74","author":"Farrah","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.clnu.2026.106781_bib58","doi-asserted-by":"crossref","DOI":"10.1590\/2175-8239-jbn-2025-0065en","article-title":"Outdated or underrated? The case for low-protein diets in CKD","volume":"47","author":"Mafra","year":"2025","journal-title":"Jornal Brasileiro de Nefrologia"},{"key":"10.1016\/j.clnu.2026.106781_bib59","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.jrn.2021.06.007","article-title":"Global policy barriers and enablers to exercise and physical activity in kidney care","volume":"32","author":"Bennett","year":"2022","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.clnu.2026.106781_bib60","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.0000001019","article-title":"Addressing the threat to kidney health from modern diets: need for a societal approach","author":"Goraya","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clnu.2026.106781_bib61","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/joim.20117","article-title":"Low-protein diet for chronic kidney disease: evidence, controversies, and practical guidelines","volume":"298","author":"Mafra","year":"2025","journal-title":"J Intern Med"},{"key":"10.1016\/j.clnu.2026.106781_bib62","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI Clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clnu.2026.106781_bib63","article-title":"Low protein diets for non-diabetic adults with chronic kidney disease","volume":"10","author":"Hahn","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clnu.2026.106781_bib64","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/jcsm.12264","article-title":"Low-protein diet for conservative management of chronic kidney disease: a systematic review and meta-analysis of controlled trials","volume":"9","author":"Rhee","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnu.2026.106781_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206134","article-title":"Effect of diet protein restriction on progression of chronic kidney disease: a systematic review and meta-analysis","volume":"13","author":"Yan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clnu.2026.106781_bib66","doi-asserted-by":"crossref","first-page":"e2127","DOI":"10.1093\/nutrit\/nuae178","article-title":"Effects of a low-protein diet on kidney function in patients with chronic kidney disease: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials","volume":"83","author":"Amiri Khosroshahi","year":"2025","journal-title":"Nutr Rev"},{"key":"10.1016\/j.clnu.2026.106781_bib67","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnu.2026.106781_bib68","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clnu.2026.106781_bib69","article-title":"Low-protein diet adherence and CKD progression during long-term follow-up","volume":"41","author":"Brum","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clnu.2026.106781_bib70","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.9575","article-title":"Protein intake and kidney outcomes in nondialysis chronic kidney disease over 15 years","volume":"9","author":"Beberashvili","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clnu.2026.106781_bib71","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/ndt\/gfae077","article-title":"The safety of a low-protein diet in older adults with advanced chronic kidney disease","volume":"39","author":"Windahl","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clnu.2026.106781_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/nu16101498","article-title":"Low-Protein diet in elderly patients with chronic kidney disease stage 4 and 5 in conservative management: Focus on Sarcopenia development","volume":"16","author":"Martino","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2026.106781_bib73","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","article-title":"Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial","volume":"13","author":"Sattar","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clnu.2026.106781_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnha.2025.100652","article-title":"Weighing the risk of GLP-1 treatment in older adults: should we be concerned about sarcopenic obesity?","volume":"29","author":"Prokopidis","year":"2025","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.clnu.2026.106781_bib75","article-title":"Unravelling sarcopenia in chronic kidney disease: from pathogenesis to diagnosis and therapeutics","volume":"16","author":"Vallianou","year":"2026","journal-title":"Diagnostics (Basel)"},{"issue":"Suppl 2","key":"10.1016\/j.clnu.2026.106781_bib76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ggi.70275","article-title":"Guidelines for nutritional management of Sarcopenia and Frailty 2025","volume":"25","author":"Kuzuya","year":"2025","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.clnu.2026.106781_bib77","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/ndt\/gfae200","article-title":"Effects of dietary interventions for metabolic acidosis in chronic kidney disease: a systematic review and meta-analysis","volume":"40","author":"Mahboobi","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clnu.2026.106781_bib78","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/j.jrn.2024.03.001","article-title":"The role of dietary acid load on progression of estimated glomerular filtration rate among individuals diagnosed with chronic kidney disease","volume":"34","author":"Poyourow","year":"2024","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.clnu.2026.106781_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151425","article-title":"Diet and metabolism in CKD-related metabolic acidosis","volume":"43","author":"Vincent-Johnson","year":"2023","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.clnu.2026.106781_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/nu13082534","article-title":"Nutritional approaches for the management of metabolic acidosis in chronic kidney disease","volume":"13","author":"Noce","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2026.106781_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.360","article-title":"Potassium management with finerenone: practical aspects","volume":"5","author":"Wanner","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.clnu.2026.106781_bib82","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clnu.2026.106781_bib83","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ndt\/gfad026","article-title":"SGLT2 inhibitors: new kids on the block to control hyperkalemia","volume":"38","author":"Gabai","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clnu.2026.106781_bib84","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ajcnut.2024.09.006","article-title":"Dietary plant-to-animal protein ratio and risk of cardiovascular disease in 3 prospective cohorts","volume":"120","author":"Glenn","year":"2024","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2026.106781_bib85","article-title":"The modulatory role of bioactive compounds in functional foods on inflammation and metabolic pathways in chronic diseases","volume":"14","author":"Ma","year":"2025","journal-title":"Foods"},{"key":"10.1016\/j.clnu.2026.106781_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-20266-5","article-title":"Dietary composition modulate gut microbiota and related biomarkers in patients with chronic kidney disease","volume":"15","author":"Udomkarnjananun","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2026.106781_bib87","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2215\/CJN.0000000705","article-title":"Dietary intake and gut microbiome in CKD","volume":"20","author":"Kemp","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clnu.2026.106781_bib88","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1136\/gutjnl-2024-334634","article-title":"Toxic microbiome and progression of chronic kidney disease: insights from a longitudinal CKD-microbiome study","volume":"74","author":"Laiola","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.clnu.2026.106781_bib89","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf351","article-title":"Gut microbiota modulation in GLP-1RA and SGLT-2i therapy: clinical implications and mechanistic insights in type 2 diabetes","volume":"18","author":"Kanbay","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.clnu.2026.106781_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/life15060843","article-title":"Bidirectional interactions between the gut microbiota and incretin-based therapies","volume":"15","author":"Trapanese","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.clnu.2026.106781_bib91","article-title":"The interplay between GLP-1-Based therapies, the gut microbiome, and MASLD\/MASH in type 2 diabetes mellitus: a narrative review","volume":"14","author":"Dinkov","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.clnu.2026.106781_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1139\/cjpp-2025-0219","article-title":"The potential for complex interplay between GLP-1 receptor agonists, gut microbiome, and obesity management","volume":"104","author":"Johnson","year":"2026","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.clnu.2026.106781_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2025.104379","article-title":"Pharmacomicrobiomics: exploring the role of gut microbiota in type 2 diabetes and antidiabetic drug mechanisms","volume":"36","author":"Wen","year":"2026","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.clnu.2026.106781_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clicom.2025.12.001","article-title":"The impact of diet on gut microbiome composition: implications for immune-mediated diseases","volume":"9","author":"Rondinella","year":"2026","journal-title":"Clinical Immunology Communications"},{"key":"10.1016\/j.clnu.2026.106781_bib95","doi-asserted-by":"crossref","DOI":"10.1038\/s44324-025-00066-1","article-title":"Mechanisms and implications of the gut microbial modulation of intestinal metabolic processes","volume":"3","author":"Jyoti","year":"2025","journal-title":"Npj Metabolic Health and Disease"},{"key":"10.1016\/j.clnu.2026.106781_bib96","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ajcn\/nqac054","article-title":"Serum metabolomic signatures of plant-based diets and incident chronic kidney disease","volume":"116","author":"Kim","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2026.106781_bib97","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13146","article-title":"Ultraprocessed food and chronic noncommunicable diseases: a systematic review and meta-analysis of 43 observational studies","volume":"22","author":"Lane","year":"2021","journal-title":"Obes Rev"},{"key":"10.1016\/j.clnu.2026.106781_bib98","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/j.jrn.2023.10.007","article-title":"Plasma metabolomics of dietary intake of protein-rich foods and kidney disease progression in children","volume":"34","author":"Ren","year":"2024","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.clnu.2026.106781_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/metabo15030211","article-title":"Diet-induced proteomic and metabolomic signatures in chronic kidney disease: a precision nutrition approach","volume":"15","author":"Caba\u0142a","year":"2025","journal-title":"Metabolites"},{"key":"10.1016\/j.clnu.2026.106781_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/s41538-025-00597-3","article-title":"Metabolomic signature of ultraprocessed food consumption and microvascular complications among individuals with type 2 diabetes","volume":"9","author":"Li","year":"2025","journal-title":"npj Sci Food"},{"key":"10.1016\/j.clnu.2026.106781_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/nu15122715","article-title":"Nutritional treatment as a synergic intervention to pharmacological therapy in CKD patients","volume":"15","author":"Giannese","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2026.106781_bib102","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-026-04266-0","article-title":"An atlas of exposome-phenome associations in health and disease risk","volume":"32","author":"Patel","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.clnu.2026.106781_bib103","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.ajkd.2022.08.013","article-title":"Risks and benefits of different dietary patterns in CKD","volume":"81","author":"Joshi","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clnu.2026.106781_bib104","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jacc.2024.05.057","article-title":"Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S. health systems","volume":"84","author":"Shin","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561426002086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561426002086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:35:26Z","timestamp":1789828526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561426002086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":104,"alternative-id":["S0261561426002086"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2026.106781","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modern pharmacological therapies in nephrology: Progress, promises, and the forgotten role of diet","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2026.106781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106781"}}